Search results for "Prostatic adenocarcinoma"

showing 3 items of 3 documents

Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial.

1980

Summary— Forty-two patients with previously untreated T3/4 N1-4 MO/1 prostatic adenocarcinoma were treated with either cyproterone acetate (n=21; 300 mg intramuscularly per week) or oestradiol undecylate (n=21; 100 mg intramuscularly per month) after extensive staging which included open skeletal biopsy and pelvic lymphadenectomy in some cases. Subjective and objective parameters as well as signs of drug toxicity were recorded regularly. Evaluation after 6 months showed cyproterone acetate to be more effective in the following respects: (1) the significantly different castration effect as judged by plasma testosterone, (2) the objective voiding pattern and tumour response, with regression o…

Malemedicine.medical_specialtyTime FactorsUrologyUrologyAdenocarcinomachemistry.chemical_compoundRandom AllocationBiopsymedicineHumansCyproteronePelvic lymphadenectomyDrug toxicityTestosteroneAgedClinical Trials as Topicmedicine.diagnostic_testEstradiolProstatic adenocarcinomabusiness.industryCyproterone acetateCancerProstatic NeoplasmsMiddle Agedmedicine.diseaseSurgeryCastrationchemistrybusinessBritish journal of urology
researchProduct

PSA and second-line therapy of hormone refractory prostate carcinoma

2001

The aim of the present study was to correlate PSA response with subjective response (bone pain and performance status), in patients treated for hormone refractory carcinoma of the prostate. Twenty-four patients were introduced into the study. Median PSA was 198 ng/ml. Symptom score, performance status and PSA were monitored monthly for 3 months and then 3-monthly. Sixteen patients (66%) showed a PSA response (median value 10 ng/ml). In 8 patients (33%) PSA was 4 ng/ml. In conclusion, PSA response is not always related to subjective improvement and does not always implicate a beneficial effect of the therapy for the patient. Copyright © 2001 S. Karger AG, Basel.

OncologyMalemedicine.medical_specialtyPathologyHormone refractorymedicine.drug_classUrologyAdenocarcinomaAntiandrogenSettore MED/24 - UrologiaPSAProstateInternal medicineCarcinomamedicineHumansHormone refractoryBone painAgedAged 80 and overPerformance statusbusiness.industryProstateProstatic NeoplasmsMiddle AgedProstate-Specific Antigenmedicine.diseaseProstate-specific antigenmedicine.anatomical_structureProstatic adenocarcinomaAdenocarcinomamedicine.symptombusiness
researchProduct

Prostatic adenocarcinoma with mandibular metastatic lesion : case report

2007

Metastatic lesions of primary tumors, which originate in different parts of the body, comprise almost 1 % of different types of oral cancers. These lesions can affect either bones or soft tissues in the maxillofacial region. Whenever the maxillofacial area is affected, the most common location is in the molar region of the mandible. The clinical presentation of mandibular metastasis follows a clinical pattern characterized by irradiated dental pain in the third molar region. The most frequent sign is parethesia of the area innervated by the mandibular alveolar dental nerve. Differential diagnosis and treatment of these patients can be extremely difficult because there a number of pathologic…

stomatognathic systemMaxillofacial osseous metastasisUNESCO::CIENCIAS MÉDICASprostatic adenocarcinoma:CIENCIAS MÉDICAS [UNESCO]
researchProduct